Xencor
Biotechnology, 111 W Lemon Ave, Pasadena, California, 91016, United States, 201-500 Employees
Phone Number: 87********
Who is XENCOR
Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering ...
Read More
-
Headquarters: 111 W Lemon Ave, Pasadena, California, 91016, United States
-
Date Founded: 1997
-
Employees: 201-500
-
Revenue: $250 Million to $500 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 621511 |
Show More
Xencor Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Xencor
Answer: Xencor's headquarters are located at 111 W Lemon Ave, Pasadena, California, 91016, United States
Answer: Xencor's phone number is 87********
Answer: Xencor's official website is https://xencor.com
Answer: Xencor's revenue is $250 Million to $500 Million
Answer: Xencor's SIC: 2834
Answer: Xencor's NAICS: 621511
Answer: Xencor has 201-500 employees
Answer: Xencor is in Biotechnology
Answer: Xencor contact info: Phone number: 87******** Website: https://xencor.com
Answer: Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At Xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics antibodies that target new biological mechanisms and are more potent, safer and longer lasting to improve patient outcomes and quality of life. Our XmAb antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. This combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. The XmAb platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by Xencor and by pharmaceutical partners. Xencor is also discovering biologics products that improve the performance of old antibody drugs, known as biosuperiors, to benefit patients, ease compliance and help reduce costs.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month